Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10383)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
BTK
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2) [Suppressor; Marker]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | |||
Responsed Drug | Ibrutinib | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
NCI-H508 cells | Cecum adenocarcinoma | Homo sapiens | CVCL_1564 | |
LoVo cells | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | ||
LS513 cells | Cecum adenocarcinoma | Homo sapiens | CVCL_1386 | ||
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | ||
SW480 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | ||
SW620 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | ||
SW1116 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0544 | ||
DLD-1 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | ||
HT-29 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0320 | ||
Caco-2 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | ||
In Vivo Model |
Sixty mice were randomly divided into six groups, (1) the CRC model group (model), (2) mice with RSL3 treatment, (3) mice with Erastin treatment, (4) mice with Ibrutinib treatment, (5) mice with RSL3 and Ibrutinib treatment, and (6) Erastin and Ibrutinib group. Murine subcutaneous tumor model and xenograft tumor mouse model were established and please refer to supplemental method for details. For CRC model group, the mice were treated with PBS for two weeks. For RSL3 group, the mice were intraperitoneal injected with RSL3 (5 mg/kg daily) for two weeks. For Erastin group, the mice were intraperitoneal injected with Erastin (30 mg/kg, twice every other day) for two weeks. For Ibrutinib treatment group, mice were administered in drinking water at a concentration of 0.16 mg/ml for two weeks. Mice were also treated in combination with RSL and Ibrutinib or Erastin and Ibrutinib.
Click to Show/Hide
|
||||
Response regulation | Ibrutinib inhibited BTK, which prevented Nrf2 translocating to cell nucleus and the activation of the Nrf2 dependent antioxidant genes during oxidative stress conditions and eventually enhanced the sensitivity of Colorectal cancer (CRC) cells to ferroptosis. | ||||
Colorectal cancer [ICD-11: 2B91]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Tyrosine-protein kinase BTK (BTK) | Protein coding | |||
Responsed Drug | Ibrutinib | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
NCI-H508 cells | Cecum adenocarcinoma | Homo sapiens | CVCL_1564 | |
LoVo cells | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | ||
LS513 cells | Cecum adenocarcinoma | Homo sapiens | CVCL_1386 | ||
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | ||
SW480 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | ||
SW620 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | ||
SW1116 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0544 | ||
DLD-1 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | ||
HT-29 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0320 | ||
Caco-2 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | ||
In Vivo Model |
Sixty mice were randomly divided into six groups, (1) the CRC model group (model), (2) mice with RSL3 treatment, (3) mice with Erastin treatment, (4) mice with Ibrutinib treatment, (5) mice with RSL3 and Ibrutinib treatment, and (6) Erastin and Ibrutinib group. Murine subcutaneous tumor model and xenograft tumor mouse model were established and please refer to supplemental method for details. For CRC model group, the mice were treated with PBS for two weeks. For RSL3 group, the mice were intraperitoneal injected with RSL3 (5 mg/kg daily) for two weeks. For Erastin group, the mice were intraperitoneal injected with Erastin (30 mg/kg, twice every other day) for two weeks. For Ibrutinib treatment group, mice were administered in drinking water at a concentration of 0.16 mg/ml for two weeks. Mice were also treated in combination with RSL and Ibrutinib or Erastin and Ibrutinib.
Click to Show/Hide
|
||||
Response regulation | Ibrutinib inhibited BTK, which prevented Nrf2 translocating to cell nucleus and the activation of the Nrf2 dependent antioxidant genes during oxidative stress conditions and eventually enhanced the sensitivity of Colorectal cancer (CRC) cells to ferroptosis. | ||||
Ibrutinib
[Investigative]
In total 1 item(s) under this drug | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | ||||
Drug for Ferroptosis | Inducer | ||||
Response Target | Nuclear factor erythroid 2-related factor 2 (NFE2L2) | Suppressor; Marker | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
NCI-H508 cells | Cecum adenocarcinoma | Homo sapiens | CVCL_1564 | |
LoVo cells | Colon adenocarcinoma | Homo sapiens | CVCL_0399 | ||
LS513 cells | Cecum adenocarcinoma | Homo sapiens | CVCL_1386 | ||
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | ||
SW480 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | ||
SW620 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0547 | ||
SW1116 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0544 | ||
DLD-1 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0248 | ||
HT-29 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0320 | ||
Caco-2 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | ||
In Vivo Model |
Sixty mice were randomly divided into six groups, (1) the CRC model group (model), (2) mice with RSL3 treatment, (3) mice with Erastin treatment, (4) mice with Ibrutinib treatment, (5) mice with RSL3 and Ibrutinib treatment, and (6) Erastin and Ibrutinib group. Murine subcutaneous tumor model and xenograft tumor mouse model were established and please refer to supplemental method for details. For CRC model group, the mice were treated with PBS for two weeks. For RSL3 group, the mice were intraperitoneal injected with RSL3 (5 mg/kg daily) for two weeks. For Erastin group, the mice were intraperitoneal injected with Erastin (30 mg/kg, twice every other day) for two weeks. For Ibrutinib treatment group, mice were administered in drinking water at a concentration of 0.16 mg/ml for two weeks. Mice were also treated in combination with RSL and Ibrutinib or Erastin and Ibrutinib.
Click to Show/Hide
|
||||
Response regulation | Ibrutinib inhibited BTK, which prevented Nrf2 translocating to cell nucleus and the activation of the Nrf2 dependent antioxidant genes during oxidative stress conditions and eventually enhanced the sensitivity of Colorectal cancer (CRC) cells to ferroptosis. | ||||